Author:
Saharia Kapil K.,Husson Jennifer S.,Niederhaus Silke V.,Iraguha Thierry,Avila Stephanie V.,Yoo Youngchae J.,Hardy Nancy M.,Fan Xiaoxuan,Omili Destiny,Crane Alice,Carrier Amber,Xie Wen Y.,Vander Mause Erica,Hankey Kim,Bauman Sheri,Lesho Patricia,Mannuel Heather D.,Ahuja Ashish,Mathew Minu,Avruch James,Baddley John,Goloubeva Olga,Shetty Kirti,Dahiya Saurabh,Rapoport Aaron P.,Luetkens Tim,Atanackovic Djordje
Abstract
ABSTRACTBackgroundSolid organ transplant recipients (SOTR), who typically receive post-transplant immunosuppression, show increased COVID-19-related mortality. It is unclear whether an additional dose of COVID-19 vaccines in SOTR can overcome the reduced immune responsiveness against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants.MethodsWe performed a prospective cohort study of 53 SOTR receiving SARS-CoV-2 vaccination into a prospective cohort study performing detailed immunoprofiling of humoral immune responses against SARS-CoV-2 and its variants.ResultsPrior to the additional vaccine dose, 60.3% of SOTR showed no measurable neutralization and only 18.9% demonstrated neutralizing activity of >90% following two vaccine doses. More intensive immunosuppression, antimetabolites in particular, negatively impacted antiviral immunity. While absolute IgG levels were lower in SOTR than controls, antibody titers against microbial recall antigens were in fact higher. In contrast, SOTR showed reduced vaccine-induced IgG/IgA antibody titers against SARS-CoV-2 and its delta variants. Vaccinated SOTR showed a markedly fewer linear B cell epitopes, indicating reduced B cell diversity. Importantly, a third vaccine dose led to an increase in anti-SARS-CoV-2 antibody titers and neutralizing activity across alpha, beta and delta variants. However, we observed a significant decrease in anti-spike antibody titers with the omicron variant.ConclusionsOnly a small subgroup of SOTR generated functionally relevant antibodies after completing the initial vaccine series based on dysfunctional priming of immune responses against novel antigens. An additional dose of the vaccine results in dramatically improved antibody responses against all SARS-CoV-2 variants except omicron.
Publisher
Cold Spring Harbor Laboratory